Key facts
- Claris Bio’s last known valuation is $163.4M (Nov 2025).
- It has raised $153.6M across 1 recorded rounds; the latest was Later Stage VC (Series A) ($54.5M) in Jan 2024.
- Notable investors include RA Capital Management, Novo Holdings, Catalio Capital Management, Janus Henderson Investors, Mass General Brigham Ventures.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Claris Bio
Funding rounds
1 roundsAbout Claris Bio
Developer of a topical formulation technology designed to treat orphan ophthalmic disorders. The company's technology creates a recombinant hepatocyte growth factor that accelerates the healing process, enabling healthcare professionals to get access to noninvasive treatment and patients to recover and stay fit.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Jersey City, NJ, United States
- Founded
- 2018
- Employees
- 5
- Website
- clarisbio.com/
- Ownership
- Privately Held (backing)
Claris Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Claris Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Claris Bio in its N-PORT filings yet. We sweep new filings monthly.